Pascal Soriot says Japan’s current drug‑price caps could force multinational pharma to postpone or cancel launches, urging a floor of 60 % of U.S. prices. The warning comes as Japan’s health‑spending share falls and the government weighs reforms that could reshape R&D investment and manufacturing in the country.
Business news
AstraZeneca chief executive Pascal Soriot told a Tokyo press conference on 26 May 2026 that Japan must set drug‑price ceilings at no lower than 60 % of U.S. list prices. He warned that the current pricing regime – which often forces new medicines to be priced at 30‑40 % of U.S. levels – is prompting global innovators to delay, scale‑back, or skip launches in Japan. In his view, the pricing gap creates a “price‑spill‑over” risk: once a low price is established in Japan, U.S. payers and insurers may demand similar discounts, eroding revenue streams that fund R&D.
Soriot’s remarks follow a recent internal AstraZeneca analysis that projected $1.2 billion of 2027‑2030 revenue could be lost if the company were to forego Japanese introductions of its next‑generation oncology and respiratory pipelines. The analysis also estimated that a 60 % price floor would preserve roughly $750 million of incremental sales while still delivering a 15 % discount to Japanese patients relative to U.S. list prices.
Market context
Japan accounts for 10 % of global pharmaceutical sales, but its average drug‑price discount sits at about 35 % of U.S. list prices, the lowest among the G7. The Ministry of Health, Labour and Welfare (MHLW) uses a reference pricing system that benchmarks new products against a basket of domestic and foreign prices, often pulling the ceiling down.
In fiscal 2025, Japan’s total health‑care expenditure reached ¥55 trillion ($380 billion), with pharmaceuticals representing ¥12 trillion ($83 billion) – a modest share compared with the United States, where drug spend exceeds $550 billion. However, Japan’s aging population (28 % over 65) creates a growing demand for high‑cost biologics and gene therapies, making the pricing debate increasingly strategic.
The United States, by contrast, operates under a fragmented pricing model where manufacturers set list prices and negotiate rebates with insurers and pharmacy benefit managers. The resulting list‑price‑to‑net‑price gap can exceed 50 %, but the headline price remains high, supporting robust R&D budgets. AstraZeneca’s global R&D spend in 2025 was $7.6 billion, funded largely by revenues from high‑price markets.
Recent policy moves in Japan, such as the 2024 “price‑reduction ceiling” that capped annual price cuts at 5 % for new drugs, have been criticised by industry groups for squeezing margins. At the same time, the government has pledged ¥200 billion ($1.4 billion) in incentives for domestic drug‑manufacturing and a tax credit of up to 30 % for R&D conducted in Japan, signaling a desire to retain and attract investment.
What it means
Launch timing risk – If the pricing floor is not raised, AstraZeneca and peers may postpone the Japanese roll‑out of pipeline assets such as the lung‑cancer antibody‑drug conjugate (ADC) AZ‑D123 and the type‑2 diabetes GLP‑1 analogue AZ‑G456. Delays could push Japanese patients’ access back by 12‑24 months, eroding market share to competitors that accept lower prices.
R&D location decisions – A more predictable pricing environment would make Japan a more attractive site for clinical‑trial hubs and manufacturing plants. AstraZeneca has already earmarked ¥30 billion ($210 million) for a new biologics facility in Osaka, contingent on a stable pricing framework.
Budget impact for the MHLW – Raising the floor to 60 % of U.S. prices would increase the government’s drug‑spending outlook by an estimated ¥150 billion ($1.0 billion) annually. However, the Ministry could offset part of this rise through the aforementioned tax credits and by negotiating value‑based contracts that tie reimbursement to real‑world outcomes.
Competitive dynamics – Smaller Japanese firms, such as Daiichi Sankyo, which announced a $600 million commitment to keep drug discovery domestic, may benefit from a pricing regime that narrows the gap with multinational peers, encouraging joint‑development agreements.
Investor perception – Analysts at Morgan Stanley and Nomura have downgraded Japan‑focused pharma stocks by an average of 3 % since the 2024 price‑reduction ceiling was introduced. A policy shift toward a higher floor could reverse that trend, lifting the Japan Pharma Index by 2‑3 % over the next twelve months.
In sum, Soriot’s warning underscores a classic trade‑off: lower prices improve short‑term affordability but risk long‑term innovation pipelines. For Japan, the decision will shape not only the timing of the next wave of breakthrough medicines but also the country’s role as a hub for high‑value drug manufacturing and research.
For further reading, see the Ministry of Health’s 2025 pricing reform white paper and AstraZeneca’s 2025 annual report (pages 34‑38).
Comments
Please log in or register to join the discussion